

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 8, 2019

Medtronic Public Limited Company

(Exact name of Registrant as Specified in its Charter)

Ireland
(State or other jurisdiction
of incorporation)

1-36820
(Commission
File Number)

98-1183488
(IRS Employer
Identification No.)

20 On Hatch, Lower Hatch Street, Dublin 2, Ireland
(Address of principal executive offices)

+353 1 438-1700
(Registrant's telephone number, including area code):

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On March 8, 2019, the Board of Directors (the “Board”) of Medtronic plc (the “Company”) increased the size of the Board from 10 to 11 and appointed Andrea Goldsmith, Ph.D., as a new director of the Company effective as of March 11, 2019. Dr. Goldsmith will serve until the Company’s 2019 Annual Meeting of Shareholders, at which time she will be a nominee for election to the Board by a vote of the Company’s shareholders. The Board has not yet determined Dr. Goldsmith’s committee assignments.

In connection with her appointment to the Board of Directors, pursuant to the Company’s non-employee director compensation policy, Dr. Goldsmith will be eligible to receive an annual cash retainer and a director equity grant, in each case as described under “Corporate Governance-Director Compensation” in the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on August 24, 2018.

There were no arrangements or understandings between Dr. Goldsmith and any other persons pursuant to which she was selected as a director, and neither Dr. Goldsmith nor any of her immediate family has been a party to any transaction or currently proposed transaction with the Company that is reportable under Item 404(a) of Regulation S-K.

A press release announcing her appointment was issued on March 14, 2019. A copy of such press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits

(d) [Exhibit 99.1](#) Press release of Medtronic plc dated March 14, 2019.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDTRONIC PUBLIC LIMITED COMPANY

Date: March 14, 2019

By /s/ Bradley E. Lerman
Bradley E. Lerman
Senior Vice President, General Counsel and Corporate
Secretary



NEWS RELEASE

Contacts:

Fernando Vivanco
Public Relations
+1-763-505-3780

Ryan Weispenning
Investor Relations
+1-763-505-4626

FOR IMMEDIATE RELEASE**MEDTRONIC BOARD APPOINTS ANDREA J. GOLDSMITH, PH.D. AS A NEW DIRECTOR**

DUBLIN - March 14, 2019 - Medtronic plc (NYSE:MDT) today announced that its Board of Directors has appointed Andrea J. Goldsmith, Ph.D. to the Board as an independent director, effective March 11, 2019.

Dr. Goldsmith is the Stephen Harris professor in the School of Engineering at Stanford University and director of Stanford's Wireless Systems Laboratory. Her research focuses on state-of-the-art wireless system design and the application of information theory and signal processing to neuroscience. Dr. Goldsmith is a widely published expert on this topic and the recipient of multiple awards and honors for her research, including IEEE Fellow. She co-founded and served as Chief Technology Officer of Plume WiFi (formerly Accelera, Inc.) and Quantenna Communications, Inc., and previously held positions at Maxim Technologies, MemoryLink Corporation, and AT&T Bell Laboratories. Previously, she was an assistant professor of Electrical Engineering at the California Institute of Technology.

"We are delighted to have Dr. Goldsmith join our Board of Directors," said Omar Ishrak, Medtronic chairman and chief executive officer. "With her expertise in wireless system design and the application of information theory and signal processing to biology and neuroscience, she will be a valued adviser as we work to fulfill our Mission to alleviate pain, restore health and extend life for people around the world."

Dr. Goldsmith currently serves on the Board of Directors for Crown Castle International Corp. She is also co-principal investigator for the NSF Center for Science of Information and is on the technical advisory boards of Sequans Communications and Cohere Technologies. She is a member of the National Academy of Engineering and the American Academy of Arts and Sciences. She received her B.S., M.S. and Ph.D degrees from the University of California at Berkeley.

About Medtronic

Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 86,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-